您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 影响血液及造血系统药物->促白细胞生成药物
处方药:处方药
包装规格: 300微克/毫升/瓶 10瓶/盒
计价单位:
  点击放大  
生产厂家中文参考译名:
安进
生产厂家英文名:
Amgen
该药品相关信息网址1:
http://www.neupogen.com/pi.html
该药品相关信息网址2:
http://www.drugs.com/neupogen.html
该药品相关信息网址3:
http://www.rxlist.com/neupogen-drug.htm
原产地英文商品名:
NEUPOGEN 300MCG/ML/VIAL 10VIALS/BOX
原产地英文药品名:
FILGRASTIM
中文参考商品译名:
优保津 300微克/毫升/瓶 10瓶/盒
中文参考化合物名称:
非格司亭
原产地国家批准上市年份:
1991/02/20
英文适应病症1:
Neutropenic patients
临床试验期:
完成
中文适应病症参考翻译1:
中性粒细胞减少症
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201181122303538.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文非格司亭处方资料(仅供参考)

【药物名称】优保津

【英文名】Filgrastim

【别名】重组人粒细胞集落刺激因子 ,惠尔血,赛格力,赛强,吉粒芬

【外文名】Filgrastim, Recombinant Human Granulocyte-Colony Stimulating Factor, rhG-CSF

【适应症】本品适用于: (1)促进骨髓移植后中性粒细胞的恢复。 (2)治疗肿瘤化疗后中性粒细胞减少症。 (3)治疗伴随骨髓异常增生综合征之中性粒细胞减少症。 (4)治疗伴随再生不良性贫血之中性粒细胞减少。 (5)治疗先天性、特发性中性粒细胞减少症。

【用量用法】 1.骨髓移植患者:于骨髓移植手术后第2日至第5日内开始,每日皮下注射或静滴本品300μg,每日1次。 2.实体瘤(肺癌、乳腺癌、卵巢癌、恶性淋巴瘤、睾丸肿瘤、神经母细胞瘤):于化疗完成24h后开始每日皮下注射75μg,每日1次。 3.白血病患者:于化疗完成24h后开始每日皮下注射或静滴300μg,每日1次。 4.伴随骨髓发育不良综合征的中性粒细胞减少症,静滴100μg,每日1次。 5.伴随再生不良性贫血的中性粒细胞减少症:通常成人的白细胞数1乘10的9次方/L以下时,静滴本品400μg,每日1次。

【注意事项】 1.少数患者有轻度骨痛、腰痛、胸痛、关节痛的情况发生,亦有少数出现暂时性的血清尿酸、乳酸脱氢酶及碱性磷酸酶增高,停药后可恢复。有时会有恶心、呕吐、SGOT、SGPT升高;皮疹偶有发生。 2.对本品有过敏反应的患者、骨髓中的芽球并没有明显减少的骨髓性白血病患者及末稍血液中可看到骨髓芽球之骨髓性白血病患者禁用。 3.本品使用中,须定期进行血液检查,要特别注意不可让中性粒细胞增加到必需数量以上,否则须采取适当的减量或停药措施。 4.为了防止过敏反应发生,使用前须详细询问病史,必要时要预先进行皮试。 5.对进行化疗的中性粒细胞减少的患者,应先给予化疗药物后再注射本品,须避免在化疗前使用。 6.已知骨髓异常增生综合征,伴随芽球增加的病例,有转移致骨髓白血病的危险,所以在使用本品时,应先采样细胞,确认并经过体外试验,末见有芽胞之增多,方可使用。 7.儿童使用本品时,应谨慎并仔细观察。 8.孕妇、早产儿、新生儿、婴儿均不宜使用。 9.静脉注射时,应与5%葡萄糖注射液或等渗盐水混合使用,但不宜与其他注射液混合注射。

【规格】针剂:75μg/支,150μg/支,300μg/支。

【类别】促进白细胞增生药

Facts About Neupogen®
When a person has received a very high dose of radiation, destruction of the bone marrow, potentially resulting in uncontrolled bleeding and infection, is a major concern. To help the recovery of the bone marrow, growth factors that stimulate the blood cells to multiply can be used. Filgrastim (trade name Neupogen®), is a drug that was approved for use by the FDA in 1991 for cancer patients with bone marrow damage due to chemotherapy or radiotherapy. Treated patients have had fewer infections, less need for intravenous antibiotics, and shortened hospital stays than those who did not receive the drug. Neupogen may also be useful for patients who have bone marrow damage from accidental exposures to high doses of radiation and it is expected to provide similar benefits.

What Neupogen Is
Filgrastim (trade name Neupogen®) is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology. It is a specific type of cytokine that stimulates the growth of white blood cells.

What Cytokines Are
Cytokines are hormone-like proteins that act as communicators between cells. They can relay messages between cells, telling them to grow, stop growing, move to a trouble spot, or otherwise change the cell's function. Neupogen® is a specific type of cytokine that stimulates the growth of white blood cells.

Use of Neupogen® to Treat Persons Accidentally Exposed to High Doses of Radiation
Just like a cancer patient who has received chemotherapy or radiation therapy, a person who has received a high dose of radiation may experience bone marrow destruction, possibly resulting in uncontrolled bleeding and infection. Since Neupogen® has been used successfully for cancer patients to stimulate the growth of the white blood cells, making them less vulnerable to infections, it is expected to help patients who have bone marrow damage from very high doses of radiation in much the same way.

How Neupogen® Works
Patients who receive very high doses of radiation often are left with very few white blood cells. The patients' own bone marrow will eventually create new blood cells, but this is a slow process. And until the white blood cell counts rise sufficiently, the patients are at a high risk of death from infection. Neupogen® can speed up the process of white blood cell creation, reducing the time that the patient is vulnerable to infection.

Who Can Take Neupogen
People may be prescribed Neupogen® following chemotherapy or radiation therapy to assist in their recovery. Also, people may be prescribed Neupogen® following a high dose of radiation from a radiation emergency.

Neupogen® is safe for most adults, but should not be taken by people who have known hypersensitivity to E. coli-derived proteins, filgrastim, or any component of filgrastim. Children and pregnant women should take Neupogen® with caution. It is not known if Neupogen® is excreted in human milk, so breastfeeding women should take Neupogen with caution as well.

Side Effects of Neupogen®
The possible side effects of Neupogen® include fever, diarrhea, skin rash and weakness. The most common side effect is mild to moderate bone pain.

How Neupogen® Is Given
Neupogen® is given by injection under the skin or through intravenous infusion.

What the Treatment Plan Is
The treatment plan is to give 5 micrograms per kilogram of patient weight (mcg/kg) of G-CSF filgrastim (Neupogen®) daily for up to 2 weeks, either by injection or intravenous infusion.

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201181122303538.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2011-8-12
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15901965168@163.com